Does CBD help in treating schizophrenia?

Cannapio seedsOur own brandBrowse ›Tip for this articleAuto Banana OG Kush - autoflowering seeds 5 pcs Cannapio€19.30Browse ›Tip for this articleAuto Pure Haze - 3pcs Cannapio Autoflowering Seeds€9.20Browse ›

Psychiatric pathologies constitute a major medical issue, impacting not only the affected individuals but also their family and social environment. Schizophrenia manifests as alterations in the perception of reality, giving rise to symptoms such as delusions and hallucinations. This neuropsychiatric condition proves to be far more complex than health professionals initially assumed. In recent decades, specialists have explored various therapeutic approaches, some of which are accompanied by significant side effects. Current scientific investigations suggest that cannabidiol (CBD) could represent a promising avenue in the management of psychotic disorders such as schizophrenia.

Understanding Schizophrenia: Definition and Characteristics

Schizophrenia constitutes a chronic psychiatric condition characterized by a distorted interpretation of reality in the affected individual. This pathology results in dysfunctions in cognitive abilities, emotional management, and an altered perception of the environment. The clinical course generally presents a fluctuation between phases of emotional numbing and episodes of stupor characterized by behavioral rigidity. According to data from the World Health Organization, this condition affects more than 26.3 million individuals worldwide. Statistics reveal that approximately 30,000 patients die annually, with a particularly high prevalence in Southeast Asia. Schizophrenia affects both sexes equally, with a typical onset in early adulthood. The current absence of a definitive curative treatment makes it a condition requiring lifelong management.

Clinical Manifestations of the Pathology

Many preconceived ideas circulate regarding schizophrenia, including the erroneous concept of a split personality; in reality, these symptoms point to other psychiatric disorders. The majority of affected individuals display neither violent behavior nor social dangerousness. Symptomatology is classified into three main categories in the medical literature: positive, negative, and cognitive symptoms. This terminology of "positive" and "negative" does not carry the usual connotation one might expect. Let us examine these different symptomatic categories in detail.

• Positive Symptoms – these are characterized by disturbed mental activity. Typical manifestations include delusional episodes with erroneous convictions and behavioral changes. These states are frequently accompanied by paranoia or hallucinations affecting hearing, vision, smell, touch, or taste. Auditory hallucinations are a recurring phenomenon in patients. Delusions also represent a characteristic aspect, with affected individuals potentially developing persecutory convictions, overestimating their abilities, or anticipating imminent catastrophes. These positive symptoms coexist with episodes of depression, anxious manifestations, and physical hyperactivity.
• Negative Symptoms – this category is manifested by a decrease in verbal expression, planning abilities, physical activity, receptivity to positive emotions, and general interest. These manifestations can compromise social relationships. Sometimes a loss of interest in essential daily activities such as personal hygiene occurs. In certain exceptional cases, the person may adopt a fixed posture for extended periods.
• Cognitive Symptoms – these manifestations encompass a disorganization and slowing of thought, difficulty concentrating, memory impairment, agitation, unexplained apathy, or regressive behaviors. Although these cognitive symptoms have less of a direct impact on the entourage, they significantly compromise the patient's professional integration.

Origins and Risk Factors

Researchers and clinicians attribute the emergence of this pathology to genetic components, environmental influences, and abnormalities in brain development. A family history of schizophrenia considerably increases the likelihood of occurrence in other family members.

• Genetic Factors – although the disease can occur without a family history, the risk rises to 6.5% when a relative has this diagnosis. In monozygotic twins, the probability exceeds 40%, while it approaches 12.5% for dizygotic twins.
• Environmental Influences – the impact concerns living environments, the use of psychoactive substances, and perinatal complications. It is noteworthy that the urban environment could double the risk of developing schizophrenia. Social isolation and the fragility of social ties also constitute determining factors.
• Brain Development – scientific investigations reveal that schizophrenic patients exhibit significant structural and functional brain alterations. The pathology also involves disruptions in the production of neurotransmitters such as dopamine and serotonin.

Conventional Therapeutic Approaches

To definitively diagnose schizophrenia, patients must undergo several examinations aimed at ruling out other psychiatric disorders or the influence of psychoactive substances. Currently, no treatment allows for a complete cure for schizophrenia, with available therapies limited to alleviating the pathological manifestations. Adverse effects sometimes force patients to seek alternatives in substance use, a potentially harmful approach. Management requires appropriate medication in the form of first or second-generation antipsychotics.

Antipsychotics and Their Limits

Administering antipsychotics produces an initial improvement after approximately 7 to 14 days, but these drugs only effectively target positive symptoms such as hallucinations, delusions, and paranoid manifestations. Other symptoms, cognitive and negative, remain refractory to antipsychotics. The majority of patients achieve at least a partial response, although in more complex situations, the use of clozapine is considered despite its severe side effects.

Common adverse effects of antipsychotics include significant weight gain and metabolic syndrome, which can trigger diabetes. Many molecules are associated with an increased risk of mortality and the development of neurodegenerative pathologies.

CBD: An Emerging Therapeutic Perspective

Cannabidiol, a non-psychoactive compound found in cannabis seeds, is the subject of in-depth investigations for its potential therapeutic properties. Preliminary research suggests that this cannabinoid could present antipsychotic characteristics without the side effects of conventional treatments. Unlike THC, CBD does not produce psychoactive effects and could even counteract certain adverse effects of tetrahydrocannabinol.

Preclinical studies indicate that CBD could act on several neurobiological systems involved in schizophrenia, including dopaminergic and serotonergic receptors. This therapeutic approach represents considerable hope for patients who do not tolerate traditional antipsychotics or who show therapeutic resistance.

Mechanisms of Action and Current Research

The pharmacological profile of CBD reveals complex interactions with the endocannabinoid system and other cerebral signaling pathways. Scientific investigations are currently exploring the optimal modes of administration and appropriate dosages to maximize therapeutic efficacy while minimizing risks.

It should be emphasized that these research efforts concern exclusively the genetic material present in cannabis seeds, studied in a scientific and botanical context. The properties of the different varieties of cannabis are the subject of in-depth analyses of their cannabinoid and terpene profiles, contributing to a better understanding of their particular genetic characteristics.